ContraFect to Chair and Participate in Virtual Superbugs & Superdrugs 2020 Conference
30 mars 2020 05h00 HE
|
ContraFect Corporation
YONKERS, N.Y., March 30, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
18 mars 2020 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., March 18, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect to Present at FDA Workshop on Advancing Animal Models for Antibacterial Drug Development
04 mars 2020 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., March 04, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Announces One-for-Ten Reverse Stock Split
04 févr. 2020 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Feb. 04, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Appoints Jane E. Ambler, Ph.D. as Vice President of Clinical Microbiology
03 févr. 2020 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Feb. 03, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Announces Oral Presentations at the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
27 janv. 2020 07h00 HE
|
ContraFect Corporation
YONKERS, New York, Jan. 27, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect Partners with Leading Orthopedic Center in Europe to Provide Compassionate Use of Exebacase to Patients with Chronic Staphylococcal Prosthetic Joint Infections
13 janv. 2020 08h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Jan. 13, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis
10 janv. 2020 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Jan. 10, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis
20 déc. 2019 08h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Dec. 20, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Announces First Gram-negative Product Candidate CF-370, a Direct Lytic Agent Targeting Pseudomonas aeruginosa
18 déc. 2019 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Dec. 18, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...